Amid ris­ing con­cern of re­sis­tance, Pfiz­er lim­its sup­ply of Paxlovid for com­bi­na­tion stud­ies — re­port

As con­cerns mount over the po­ten­tial de­vel­op­ment of re­sis­tance to Pfiz­er’s Covid-19 pill Paxlovid, the com­pa­ny has de­clined to sup­ply re­searchers with the an­tivi­ral for use in com­bi­na­tion stud­ies, ac­cord­ing to a Bloomberg re­port. 

Pfiz­er con­firmed to End­points News that it’s eval­u­at­ing a “mul­ti-pronged strat­e­gy” that in­cludes think­ing ahead to sec­ond-gen­er­a­tion an­tivi­rals and com­bi­na­tion ther­a­pies. How­ev­er, the phar­ma gi­ant has not be­gun any clin­i­cal tri­als, ac­cord­ing to a spokesper­son.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER